7-amino-5H-dibenzo[b,d]azepin-6(7H)-one | 791765-65-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯氮卓类
• 英文名称: 7-amino-5H-dibenzo[b,d]azepin-6(7H)-one
• 英文别名: (RS)-7-amino-5H,7H-dibenzo[b,d]azepin-6-one；7-amino-5,7-dihydrobenzo[d][1]benzazepin-6-one
• CAS: 791765-65-6
• 化学式: C₁₄H₁₂N₂O
• 分子量: 224.262
• InChiKey: NIDGAHURPWFSKR-UHFFFAOYSA-N

物化性质

• 沸点：
  486.6±45.0 °C(Predicted)
• 密度：
  1.219±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  17
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  55.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  7-amino-5H-dibenzo[b,d]azepin-6(7H)-one 、 Boc-D-苯丙氨酸 在 水 、 3,5-二氯水杨醛 作用下， 以 甲苯 为溶剂， 以10.7 g的产率得到(7S)-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-aminium (R)-2-(tert-butoxycarbonylamino)-3-phenylpropanoate
  参考文献：
  名称：

  Crystallization-Induced Dynamic Resolution toward the Synthesis of (S)-7-Amino-5H,7H-dibenzo[b,d]-azepin-6-one: An Important Scaffold for γ-Secretase Inhibitors

  摘要：

  An enantioselective synthesis of (S)-7-amino-5H,7H-dibenzo[b,d]azepin-6-one (S-1) is described. The key step in the sequence involved crystallization-induced dynamic resolution (CIDR) of compound 7 using Boc-D-phenylalanine as a chiral resolving agent and 3,5-dichlorosalicylaldehyde as a racemization catalyst to afford S-1 in 81% overall yield with 98.5% enantiomeric excess.

  DOI：

  10.1021/acs.oprd.6b00207
• 作为产物：
  描述：

  NA无结构图 在 盐酸 、 三氟甲磺酸 、 palladium 10% on activated carbon 、 氢气 、 双(三甲基硅烷基)氨基钾 、 三氟乙酸 、 亚硝酸异戊酯 作用下， 以 甲醇 、 甲苯 为溶剂， 生成 7-amino-5H-dibenzo[b,d]azepin-6(7H)-one
  参考文献：
  名称：

  Crystallization-Induced Dynamic Resolution toward the Synthesis of (S)-7-Amino-5H,7H-dibenzo[b,d]-azepin-6-one: An Important Scaffold for γ-Secretase Inhibitors

  摘要：

  An enantioselective synthesis of (S)-7-amino-5H,7H-dibenzo[b,d]azepin-6-one (S-1) is described. The key step in the sequence involved crystallization-induced dynamic resolution (CIDR) of compound 7 using Boc-D-phenylalanine as a chiral resolving agent and 3,5-dichlorosalicylaldehyde as a racemization catalyst to afford S-1 in 81% overall yield with 98.5% enantiomeric excess.

  DOI：

  10.1021/acs.oprd.6b00207

文献信息

• PROCESS FOR PREPARATION OF ENANTIOMERICALLY PURE COMPOUNDS
  申请人：Hoffmann-Emery Fabienne

  公开号：US20080293933A1

  公开（公告）日：2008-11-27

  The invention relates to a process for the optical resolution of a dibenzo[b,d]azepinone derivative of formula II, wherein R 1 is hydrogen or halogen and R 2 is either C 1-4 -alkyl optionally substituted with C 3-7 -cycloalkyl or benzyl which is optionally substituted with C 1-4 -alkoxy, to obtain a (S)-7-amino-5H,7H-dibenzo[b,d]azepin-6-one of formula I, wherein R 1 is as in the compound of formula II. The (S)-7-amino-5H,7H-dibenzo[b,d]azepin-6-one of formula I can be used as a chiral building block for the preparation of malonamide derivatives which have the potential to act as γ-secretase inhibitors and therefore may be useful in the treatment of Alzheimer's disease and cancer.

  该发明涉及一种用于光学分辨二苯并[b,d]氮杂环己酮衍生物的过程，其化学式为II，其中R1为氢或卤素，R2为C1-4烷基，可选择性地取代为C3-7环烷基或苄基，苄基可选择性地取代为C1-4烷氧基，以获得化学式为I的(S)-7-氨基-5H,7H-二苯并[b,d]氮杂环己酮，其中R1如化合物II的情况。化学式为I的(S)-7-氨基-5H,7H-二苯并[b,d]氮杂环己酮可用作手性构建块，用于制备马隆酰胺衍生物，这些衍生物有潜力作为γ-分泌酶抑制剂，因此可能在治疗阿尔茨海默病和癌症方面有用。
• Malonamide derivatives
  申请人：Flohr Alexander

  公开号：US20050054633A1

  公开（公告）日：2005-03-10

  The invention relates to malonamide derivatives of formula wherein each of the variables are as defined herein and to pharmaceutically acceptable acid addition salts, optically pure enantiomers, racemates and diastereomeric mixtures thereof. These compounds are γ-secretase inhibitors and may be used for the treatment of Alzheimer's disease.

  该发明涉及公式的马隆酰胺衍生物，其中每个变量如本文所定义，并且涉及药学上可接受的酸盐加合物、光学纯的对映体、拉氏体和二对映异构体混合物。这些化合物是γ-分泌酶抑制剂，可用于治疗阿尔茨海默病。
• 6-OXO-6,7-DIHYDRO-5H-DIBENZO[B,D]AZEPIN-7-YL DERIVATIVES
  申请人：Flohr Alexander

  公开号：US20080188463A1

  公开（公告）日：2008-08-07

  The invention relates to 6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl derivatives of formula I wherein R 1 , R 2 and R 3 are as defined herein. The compounds are γ-secretase inhibitors useful in the treatment of Alzheimer's disease or common cancer, including, but not limited to, cervical carcinomas and breast carcinomas and malignancies of the hematopoietic system.

  该发明涉及式I的6-氧-6,7-二氢-5H-二苯并[b,d]氮杂环庚啶-7-基衍生物，其中R1、R2和R3如本文所定义。这些化合物是γ-分泌酶抑制剂，可用于治疗阿尔茨海默病或常见癌症，包括但不限于宫颈癌和乳腺癌以及造血系统恶性肿瘤。
• [EN] MALONAMIDE DERIVATIVES BLOCKING THE ACTIVITY OF GAMA-SECRETASE<br/>[FR] DERIVES DE MALONAMIDE BLOQUANT L'ACTIVITE GAMA-SECRETASE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2005023772A1

  公开（公告）日：2005-03-17

  The invention relates to malonamide derivatives of formula (I), wherein: R1 is one of the following groups (Formulae a), b), c), d)); R2 is lower alkyl, lower alkinyl, -(CH2)n-O-lower alkyl, -(CH2)n-S-lower alkyl, -(CH2)n-CN, -(CR'R')n-CF3, -(CR'R')n-CHF2, -(CR'R')n-CH2F, -(CH2)n-C(O)O-lower alkyl, -(CH2)n-halogen, or is -(CH2)n-cycloalkyl, optionally substituted by one or more substituents, selected from the group consisting of phenyl, halogen or CF3; R',R' are independently from n and from each other hydrogen, lower alkyl, lower alkoxy, halogen or hydroxy; R3, R4 are independently from each other hydrogen, lower alkyl, lower alkoxy, phenyl or halogen; R5 is hydrogen, lower alkyl, -(CH2)n-CF3 or -(CH2)n-cycloalkyl; R6 is hydrogen or halogen; R7 is hydrogen or lower alkyl; R8 is hydrogen, lower alkyl, lower alkinyl, -(CH2)n-CF3,-(CH2)n-cycloalkyl or -(CH2)n-phenyl, optionally substituted by halogen; R9 is hydrogen, lower alkyl, -C(O)H, -C(O)-lower alkyl, -C(O)-CF3,-C(O)-CH2F,-C(O)-CHF2,-C(O)-cycloalkyl,-C(O)-(CH2)n-O-lower alkyl,-C(O)O-(CH2)n-cycloalkyl, -C(O)-phenyl, optionally substituted by one or more substituents selected from the group consisting of halogen or -C(O)O-lower alkyl, or is -S(O)2-lower alkyl, -S(O)2-CF3,-(CH2)n-cycloalkyl or is -(CH2)n-phenyl, optionally substituted by halogen; n is 0, 1, 2, 3 or 4; and to pharmaceutically suitable acid addition salts, optically pure enantiomers, racemates or diastereomeric mixture thereof. These compounds may be used for the treatment of Alzheimer's disease.

  本发明涉及式（I）的马隆酰胺衍生物，其中：R1是以下组之一（式a，b，c，d）之一；R2是较低的烷基，较低的烯烃基，-(CH2)n-O-较低的烷基，-(CH2)n-S-较低的烷基，-(CH2)n-CN，-(CR'R')n-CF3，-(CR'R')n-CHF2，-(CR'R')n-CH2F，-(CH2)n-C（O）O-较低的烷基，-(CH2)n-卤素，或者是-(CH2)n-环烷基，选自苯基，卤素或CF3的一种或多种取代基；R'，R'分别独立于n和彼此，是氢，较低的烷基，较低的烷氧基，卤素或羟基；R3，R4独立于彼此，是氢，较低的烷基，较低的烷氧基，苯基或卤素；R5是氢，较低的烷基，-(CH2)n-CF3或-(CH2)n-环烷基；R6是氢或卤素；R7是氢或较低的烷基；R8是氢，较低的烷基，较低的烯烃基，-(CH2)n-CF3，-(CH2)n-环烷基或-(CH2)n-苯基，选自卤素的一种或多种取代基；R9是氢，较低的烷基，-C（O）H，-C（O）-较低的烷基，-C（O）-CF3，-C（O）-CH2F，-C（O）-CHF2，-C（O）-环烷基，-C（O）-(CH2)n-O-较低的烷基，-C（O）O-(CH2)n-环烷基，-C（O）-苯基，选自卤素或-C（O）O-较低的烷基的一种或多种取代基，或者是-S（O）2-较低的烷基，-S（O）2-CF3，-(CH2)n-环烷基或是-(CH2)n-苯基，选自卤素的一种或多种取代基；n为0，1，2，3或4；以及药学上适用的酸盐，光学纯对映体，混合物或二对映异构体的制备方法。这些化合物可用于治疗阿尔茨海默病。
• FLUOROALKYL DIBENZOAZEPINONE COMPOUNDS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20150218104A1

  公开（公告）日：2015-08-06

  Disclosed are compounds of Formula (I): wherein R 1 is CH 2 CH2CF 3 or CH 2 CH2CH 3 ; R2 is CH 2 CH 2 CF 3 , CH 2 CH 2 CH 3 , CH 2 (cyclopropyl), phenyl, or; R3 is H; R a , R b , y, and z are defined herein. Also disclosed are methods of using such compounds to inhibit the Notch receptor, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as cancer.

  本发明涉及化合物的公式(I)： 其中R1为CH2CH2CF3或CH2CH2CH3；R2为CH2CH2CF3，CH2CH2CH3，CH2（环丙基），苯基或；R3为H；Ra，Rb，y和z在此定义。还公开了使用这种化合物来抑制Notch受体的方法以及包含这种化合物的制药组合物。这些化合物在治疗、预防或减缓多种治疗领域中的疾病或障碍方面非常有用，例如癌症。